pembrolizumab,lenvatinib
merck,eisai
['lenva', 'keynoteb61', 'renal,(-adrenal)', 'pembro']
 the #keynoteb61 phase ii trial has shown that the combination of pembrolizumab and lenvatinib in patients with non-clear cell renal cancer leads to a significant response rate.
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre